Newport-based technology consultancy de Novo Solutions is the fastest-growing private company in Wales in the annual Sunday ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...